Uhl J, Newton R C, Gross J L, Rommi W, Mochan E
Department of Inflammation, Sterling Research Group, Rennselaer, NY 12144.
Biochim Biophys Acta. 1991 Nov 21;1097(4):283-8. doi: 10.1016/0925-4439(91)90082-k.
Phorbol myristate acetate (PMA) added to human synovial fibroblast cultures caused a dose-dependent increase in the production of plasminogen activator inhibitor-type 1 (PAI-1). In addition, PMA inhibited endogenous and interleukin-1 (IL-1) induced plasminogen activator (PA) activity, while increasing mRNA PAI-1 levels. Other protein kinase C (PKC) activators, mezerein and teleocidin B4, caused similar effects. The simultaneous addition of the PKC antagonists, H-7 or staurosporine, prevented the inhibition of PA activity by PMA. This study shows that activation of PKC inhibits PA and stimulates PAI production in human synovial fibroblasts. These results suggest that activation of PKC may play an important role in regulating increased PA production associated with joint destruction in rheumatoid arthritis (RA).
添加到人类滑膜成纤维细胞培养物中的佛波醇肉豆蔻酸酯乙酸酯(PMA)导致纤溶酶原激活物抑制剂1型(PAI-1)的产生呈剂量依赖性增加。此外,PMA抑制内源性和白细胞介素-1(IL-1)诱导的纤溶酶原激活物(PA)活性,同时增加PAI-1的mRNA水平。其他蛋白激酶C(PKC)激活剂,芫花酯甲和远侧霉素B4,也产生类似的效果。同时添加PKC拮抗剂H-7或星形孢菌素可防止PMA对PA活性的抑制作用。本研究表明,PKC的激活抑制了PA,并刺激了人类滑膜成纤维细胞中PAI的产生。这些结果表明,PKC的激活可能在调节与类风湿性关节炎(RA)关节破坏相关的PA产生增加中起重要作用。